CNS Pharmaceuticals acquired worldwide rights for brain cancer drug from Houston Pharmaceuticals

This article was originally published here

CNS’ licensing agreement with HPI grants the Company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. In its agreement

The post CNS Pharmaceuticals acquired worldwide rights for brain cancer drug from Houston Pharmaceuticals appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply